BCDA
BioCardia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.90
−2.46%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +17.0%
- EBIT
- +16.5%
- EPS
- +73.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +34.2%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +2.0%
- EBIT
- -3.5%
- Net income
- -3.5%
- EPS
- +57.6%
- Free cash flow
- +7.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026